LENZ Q2 Revenue Reaches $5.5M as VIZZ Commercial Launch Gains Traction, but DTC Spending Widens Losses
LENZ sits 17% above its 52-week low of $4.68.
Summary
LENZ Therapeutics posted Q2 2026 revenue of $5.5 million, driven by early VIZZ sales and license income, but losses deepened as it invested heavily in a national DTC campaign. Cash reserves of $220 million provide a year of runway.
Key Events · Earnings and Guidance · LENZ
-
VIZZ Product Sales Reach $1.7M in Q2
Net product sales of VIZZ, the first FDA-approved aceclidine-based eye drop for presbyopia, totaled $1.7 million in Q2 2026, up from zero a year ago. Approximately 27,000 packs were sold in the quarter.
-
Total Revenue Boosted by License Income
Total Q2 revenue was $5.5 million, including $3.75 million in license revenue from a $1.3 million Everest sublicense payment and a $2.5 million milestone from Théa for the Canadian regulatory submission.
-
Operating Loss Widens on DTC Marketing Blitz
Selling, general and administrative expenses jumped 208% YoY to $39.4 million, driven by a $13.3 million increase in commercial marketing and advertising as the company launched its 'Tired of Reading Glasses' DTC campaign. Net loss was $31.9 million, or $1.02 per share.
-
Cash Runway of $220M Supports 12+ Months
Cash, cash equivalents, and marketable securities totaled $220.0 million as of June 30, 2026. Management believes this is sufficient to fund operations for at least the next 12 months.
Analysis · LENZ · Life Sciences
LENZ Therapeutics delivered its first full quarter of VIZZ commercial sales, generating $1.7 million in product revenue. Total Q2 revenue hit $5.5 million, bolstered by license payments from international partners. Operating expenses, however, surged to $39.7 million—more than triple the prior year—as the company rolled out a direct-to-consumer advertising campaign featuring Sarah Jessica Parker. The net loss widened to $31.9 million. With $220 million in cash and investments, management says it has enough runway for at least the next 12 months. The quarter also brought new licensing deals in Australia/New Zealand and a telehealth launch, expanding VIZZ's reach. The key question is whether the heavy marketing spend will translate into accelerating prescription growth in the second half of 2026.
At the time of this filing, LENZ was trading at $5.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $163.4M. The 52-week trading range was $4.68 to $50.40. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.